HINOON Pharmaceuticals: Major
Health Technology
929.10 +0.01%
Mkt Cap
49.2B
P/E (TTM)
12.43
EPS (TTM)
74.76
ROE (TTM)
32.61%
Div Yield
5.38%
Highnoon Laboratories Limited (HINOON) Financial Statements, Ratios & Dividends
About
Highnoon Laboratories Ltd. is a holding company, which engages in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. The company was founded in March 1984 and is headquartered in Lahore, Pakistan.
Financial Highlights
| FY2025 | FY2024 | ||
|---|---|---|---|
| Revenue | 27.71B | 24.64B | |
| Gross Profit | 14.67B | 12.13B | |
| Net Income | 4.13B | 3.39B | |
| EPS | 77.92 | 63.95 | |
| ROE | 32.32% | 31.04% | |
| ROA | 22.18% | 20.88% | |
| Gross Margin | 52.94% | 49.23% | |
| Net Margin | 14.90% | 13.75% | |
| Current Ratio | 3.03 | 3.02 | |
| DPS | 50.00 | 40.00 | |
| Free Cash Flow | 1.42B | 4.26B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Total Revenue | 27.71B | 24.64B | |
| Cost of Goods Sold | -13.04B | -12.51B | |
| Gross Profit | 14.67B | 12.13B | |
| SG&A Expenses | -8.22B | -6.90B | |
| Research & Development | -10.79M | -9.47M | |
| Depreciation | -417.78M | -346.67M | |
| Other Operating Expense | -69.09M | -196.11M | |
| Total Operating Expense | -21.33B | -19.61B | |
| Operating Income (EBIT) | 6.38B | 5.03B | |
| Interest Income | 55.49M | 79.39M | |
| Interest Expense | -129.73M | -406.95M | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | 108.46M | 147.66M | |
| Total Non-Operating Income | 213.72M | -20.79M | |
| Pre-Tax Income | 6.59B | 5.01B | |
| Income Tax | -2.46B | -1.62B | |
| Minority Interest | 0 | 0 | |
| Net Income | 4.13B | 3.39B | |
| EBITDA | 6.81B | 5.39B | |
| EPS (Basic) | 77.92 | 63.95 | |
| EPS (Diluted) | 77.92 | 63.95 | |
| Gross Margin | 52.94% | 49.23% | |
| Operating Margin | 23.02% | 20.43% | |
| EBITDA Margin | 24.58% | 21.88% | |
| Pre-Tax Margin | 23.79% | 20.34% | |
| Net Margin | 14.90% | 13.75% |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 32.32% | 31.04% | |
| Return on Assets (ROA) | 22.18% | 20.88% | |
| Return on Invested Capital | 31.37% | 29.31% | |
| Gross Margin | 52.94% | 49.23% | |
| Operating Margin | 23.02% | 20.43% | |
| EBITDA Margin | 24.58% | 21.88% | |
| Net Margin | 14.90% | 13.75% | |
| Pre-Tax Margin | 23.79% | 20.34% | |
| Liquidity | |||
| Current Ratio | 3.03 | 3.02 | |
| Quick Ratio | 1.76 | 1.84 | |
| Leverage | |||
| Debt / Equity | 0.06 | 0.12 | |
| Debt / Assets | 0.04 | 0.08 | |
| LT Debt / Equity | 0.03 | 0.03 | |
| LT Debt / Assets | 0.02 | 0.02 | |
| Net Debt | -2.87B | -3.80B | |
| Total Debt | 801.70M | 1.37B | |
| Efficiency | |||
| Asset Turnover | 1.49 | 1.52 | |
| Inventory Turnover | 2.29 | 2.42 | |
| Per Share | |||
| Book Value Per Share | 259.57 | 222.62 | |
| Tangible Book Per Share | 258.84 | 221.72 | |
| Cash Per Share | 69.35 | 97.50 | |
| Total Debt Per Share | 15.13 | 25.82 | |
| Working Capital Per Share | 187.86 | 166.34 | |
| Shares & Market | |||
| Total Shares Outstanding | 52,983,363 | 52,983,363 | |
| Market Cap | 54.17B | 48.65B | |
| Enterprise Value | 51.30B | 44.85B | |
| Employees | 2,563 | 2,376 | |
| Shareholders | 5,558 | 5,558 | |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Dividends Per Share | 50.00 | 40.00 | |
| Dividend Yield | 4.89% | 4.36% | |
| Payout Ratio | 64.17% | 62.54% | |
| Total Dividends Paid | -2.02B | -1.63B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| P/E Ratio | 13.12 | 14.36 | |
| P/B Ratio | 3.94 | 4.12 | |
| P/S Ratio | 1.96 | 1.97 | |
| P/CF Ratio | 28.83 | 10.73 | |
| EV/EBITDA | 7.53 | 8.32 | |
| Market Cap | 54.17B | 48.65B | |
| Enterprise Value | 51.30B | 44.85B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 28.29B | |
| Gross Profit | 16.16B | |
| Operating Income | 7.03B | |
| Net Income | 3.96B | |
| EBIT | 7.03B | |
| Free Cash Flow | 2.86B | |
| EPS (Basic) | 74.76 | |
| Margins | ||
| Gross Margin | 57.11% | |
| Operating Margin | 24.86% | |
| Net Margin | 14.00% | |
| Returns | ||
| Return on Equity (ROE) | 32.61% | |
| ROIC | 0.31% | |
| Coverage & Debt | ||
| Interest Coverage | 56.4x | |
| Dividend Coverage | 2.12 | |
| Debt / Revenue | 0.03 | |
| Valuation & Scores | ||
| P/E (TTM) | 12.43 | |
| Sloan Ratio | 9.94 | |
| Zmijewski Score | -3.59 | |
Computed Metrics (Latest Period)
| FY2025 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 32.32% | |
| Return on Tangible Equity | 32.43% | |
| Return on Tangible Assets | 22.23% | |
| Return on Total Capital | 46.01% | |
| ROCE | 45.62% | |
| Growth | ||
| EPS Diluted Growth | 0.22% | |
| Sustainable Growth Rate | 11.58% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 7 | |
| Zmijewski Score | -3.55 | |
| Sloan Ratio | 9.88 | |
| Valuation (Computed) | ||
| Graham Number | 674.58 | |
| Tobin's Q Ratio | 2.75 | |
| Leverage & Coverage | ||
| Interest Coverage | 49.2x | |
| Total Debt / Capital | 0.06% | |
| Assets / Equity (Leverage) | 1.43 | |
| Net Debt / EBITDA | -0.42 | |
| Effective Interest Rate | 11.96% | |
| Debt / Revenue | 0.03 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 6.66 | |
| Receivables Turnover | 7.41 | |
| Dividends (Computed) | ||
| Payout Ratio | 0.64% | |
| Dividend Coverage | 2.88 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 10.81M | |
| Net Income / Employee | 1.61M | |
| Oper. Income / Employee | 2.49M | |
| Total Assets / Employee | 7.69M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 19.68B | |
| Invested Capital | 14.14B | |
| Working Capital | 9.95B | |
| Book Value Per Share | 259.57 | |
| Earnings Schedule | ||
| Next Earnings Date | 3 Mar 2027 | |
| Next Fiscal Period | 2026 | |